When researchers explore peptide compounds related to fat metabolism and body composition, two names frequently appear in the same breath: AOD-9604 and HGH Fragment 176-191. Both are derived from the C-terminal region of human growth hormone (hGH), and both have attracted significant scientific interest for their potential roles in lipid metabolism. Yet they are not the same compound — and understanding the distinctions between them is essential for anyone engaged in research or sourcing decisions in this space.
This article provides a structured comparison of AOD-9604 and HGH Fragment 176-191 across their molecular structure, mechanisms of action, research history, and practical research considerations. All content is for educational and research purposes only.
What Is AOD-9604?
AOD-9604 stands for Anti-Obesity Drug 9604. It is a synthetic, stabilized peptide analog derived from amino acids 176 to 191 of the human growth hormone sequence. The key structural modification that distinguishes AOD-9604 from the raw hGH fragment is the addition of a tyrosine residue at the N-terminus, along with a disulfide bridge between Cys182 and Cys189. These structural features were specifically engineered to enhance metabolic stability and biological activity in preclinical models.
AOD-9604 was developed primarily as an investigational compound targeting fat metabolism, with the goal of isolating the lipolytic properties of human growth hormone while avoiding the insulin-desensitizing effects associated with full-length hGH. Research by Heffernan et al. (2001) published in Endocrinology demonstrated that chronic treatment with AOD9604 in obese mice produced significant reductions in body fat, with effects comparable to full-length growth hormone in terms of fat oxidation, but without the same degree of influence on insulin sensitivity or glucose metabolism (PMID: 11713213).
AOD-9604 holds a notable regulatory distinction: it received Generally Recognized As Safe (GRAS) designation from the United States Food and Drug Administration. A review by Wilding (2004) in Current Opinion in Investigational Drugs outlined the compound’s metabolic profile and noted its progression through Phase II clinical trials for obesity treatment (PMID: 15134286). Although it did not ultimately secure approval as a pharmaceutical drug for obesity, this regulatory history supports its research profile.
What Is HGH Fragment 176-191?
HGH Fragment 176-191 refers to the unmodified C-terminal peptide segment of human growth hormone, spanning amino acids 176 through 191. Unlike AOD-9604, this fragment lacks the N-terminal tyrosine addition and, depending on the specific preparation, may or may not include the stabilizing disulfide bridge present in AOD-9604.
The fragment was identified early in growth hormone research as carrying much of the molecule’s lipolytic activity. Studies showed that the C-terminal region of hGH interacts with beta-adrenergic receptors — particularly the beta-3 receptor subtype — to stimulate lipolysis (fat breakdown) in adipose tissue. This interaction does not require the full receptor binding domain responsible for hGH’s growth-promoting and insulin-antagonizing effects, which opened the possibility of a more metabolically selective compound.
HGH Fragment 176-191 is frequently listed in research chemical catalogs and sold as a separate entity from AOD-9604. However, in scientific literature, the distinction between the two is sometimes blurred, and many studies discussing “HGH Fragment 176-191” effectively describe work that used what would now be classified as AOD-9604 — particularly when the stabilized, tyrosine-modified form was used.
Structural Comparison: The Key Molecular Differences
The following table summarizes the primary structural differences between the two compounds:
| Feature | AOD-9604 | HGH Fragment 176-191 |
|---|---|---|
| Sequence origin | hGH amino acids 176-191 | hGH amino acids 176-191 |
| N-terminal modification | Tyrosine (Tyr) added | No addition (natural terminus) |
| Disulfide bridge | Present (Cys182-Cys189) | Variable by preparation |
| Molecular weight | ~1,817 Da | ~1,647 Da |
| Metabolic stability | Higher due to modifications | Lower in unmodified form |
| Regulatory status | FDA GRAS designation received | Research compound only |
These structural differences have practical implications for research. The N-terminal tyrosine on AOD-9604 enhances resistance to degradation by aminopeptidases, extending the effective window of activity in biological assays. The disulfide bridge contributes to conformational stability, potentially affecting receptor binding geometry.
Mechanism of Action: How Each Compound Works
Both compounds are understood to exert their effects primarily through interaction with beta-3 adrenergic receptors in adipose tissue. This receptor subtype plays a central role in regulating thermogenesis and lipolysis, particularly in brown adipose tissue. Activation of beta-3 receptors triggers a cascade involving cyclic AMP (cAMP) as a second messenger, ultimately activating hormone-sensitive lipase (HSL) and stimulating the release of free fatty acids from stored triglycerides.
Crucially, neither compound appears to signal through the growth hormone receptor (GHR) in the same manner as full-length hGH. This mechanistic distinction is what researchers have cited as the basis for AOD-9604’s apparent metabolic selectivity. In the Heffernan et al. (2001) study comparing full-length hGH and AOD9604 in beta-3 adrenergic receptor knockout mice, AOD9604’s lipolytic effects were significantly attenuated in knockout animals, providing evidence for beta-3 receptor dependence. The same study also noted that unlike full-length growth hormone, AOD9604 did not produce statistically significant changes in insulin-like growth factor 1 (IGF-1) levels, suggesting the IGF-1 axis is not a primary driver of its effects (PMID: 11673763).
This differs from unmodified HGH Fragment 176-191 in that the absence of the N-terminal tyrosine may reduce binding affinity at the receptor level, making AOD-9604 potentially more potent in receptor engagement on a molar basis — though direct head-to-head binding affinity comparisons in published literature are limited.
Research History Compared
AOD-9604 has a more developed preclinical and clinical research history than HGH Fragment 176-191 as a distinct compound. Much of this research was conducted through Metabolic Pharmaceuticals Ltd., which advanced AOD-9604 through multiple clinical trial phases. A review of the compound’s investigational drug status (Wilding, 2004) noted Phase II results suggesting modest anti-obesity effects in human subjects, though the trials did not meet the efficacy thresholds required for regulatory approval of an obesity indication (PMID: 15134286).
The earlier Heffernan et al. studies remain among the most frequently cited in discussions of this compound class. Their 2001 paper in Endocrinology used high-fat-diet-induced obese mice and compared chronic subcutaneous administration of full-length hGH, AOD9604, and saline controls, reporting statistically significant reductions in fat mass in treated groups without the hyperglycemic effects seen with hGH (PMID: 11713213). A companion paper in the International Journal of Obesity (Heffernan et al., 2001) focused specifically on fat oxidation outcomes (PMID: 11673763).
Separately, research published by Kwon and Park (2015) in Annals of Clinical and Laboratory Science explored AOD9604’s effects in a rabbit osteoarthritis model, finding that intra-articular injection produced structural benefits in cartilage preservation — an application area distinct from the original obesity focus (PMID: 26275694). This research trajectory illustrates how the compound’s research profile has expanded beyond its original investigational indication.
HGH Fragment 176-191, as a distinct entity without the AOD-9604 modifications, has a thinner dedicated research record. Many papers cited in support of “HGH Fragment 176-191” activity appear, upon closer examination, to have used the AOD-9604 formulation. Researchers sourcing or referencing this compound for in vitro or in vivo studies should verify which specific form — modified or unmodified — was used in any study they intend to replicate or build upon.
Practical Research Considerations
For researchers evaluating these two compounds for study design, several practical considerations apply:
Purity and Characterization
Given the structural similarity between AOD-9604 and HGH Fragment 176-191, high-performance liquid chromatography (HPLC) purity data and mass spectrometry confirmation are essential for distinguishing the two compounds. A certificate of analysis should confirm molecular weight and purity to ensure the compound in hand matches the research intent. For guidance on reading peptide certificates of analysis, see the CertaPeptides COA reading guide.
Stability Profiles
Due to the structural modifications in AOD-9604, it generally demonstrates superior stability under standard laboratory conditions compared to the unmodified fragment. Both compounds should be stored lyophilized and protected from light and temperature fluctuations prior to reconstitution.
Receptor Selectivity Research Design
Researchers designing receptor binding or downstream signaling assays should account for the difference in beta-3 adrenergic receptor dependence. Studies using beta-3 receptor knockout models or specific receptor antagonists will likely yield different results for AOD-9604 versus unmodified fragment preparations, as Heffernan et al. (2001) demonstrated with knockout mouse experiments.
Literature Disambiguation
When reviewing the literature, note that “HGH Fragment 176-191” in older papers sometimes refers to the AOD-9604 formulation. Cross-referencing the molecular weight and structural description in the Methods section of cited papers is necessary to determine which compound was actually studied.
For researchers interested in sourcing AOD-9604 for laboratory use, CertaPeptides AOD-9604 is available with full certificate of analysis documentation. Related educational content on AOD-9604’s mechanisms and applications is available in the AOD-9604 research guide.
Key Takeaways
- AOD-9604 is a structurally modified analog of HGH Fragment 176-191, with an added N-terminal tyrosine and a stabilizing disulfide bridge that improve metabolic stability and receptor engagement.
- Both compounds target beta-3 adrenergic receptors to stimulate lipolysis, without activating the full hGH receptor pathway that drives IGF-1 release and insulin antagonism.
- AOD-9604 has a more extensive clinical research record, including Phase II trials and FDA GRAS designation; HGH Fragment 176-191 as an unmodified compound has limited dedicated literature.
- Many older papers citing “HGH Fragment 176-191” used the AOD-9604 formulation — researchers should verify structural details before drawing equivalence conclusions.
- For research purposes, AOD-9604 is generally the better-characterized compound, with published in vivo data in obese animal models and human clinical trials.
Frequently Asked Questions
Are AOD-9604 and HGH Fragment 176-191 the same compound?
No. AOD-9604 is a modified analog of HGH Fragment 176-191, with the addition of a tyrosine residue at the N-terminus and a disulfide bridge between cysteine residues 182 and 189. These modifications improve its stability and likely affect receptor binding characteristics. Unmodified HGH Fragment 176-191 lacks these structural features.
Which compound has more published research?
AOD-9604 has significantly more published preclinical and clinical research. It was the subject of Phase II clinical trials for obesity and received FDA GRAS designation. HGH Fragment 176-191 in its unmodified form has limited dedicated research, though some older papers use the two terms interchangeably.
Does either compound raise IGF-1 levels in research models?
Based on available preclinical data, AOD-9604 does not appear to significantly raise IGF-1 levels at doses that produce lipolytic effects, in contrast to full-length growth hormone. This selectivity was noted in the Heffernan et al. (2001) studies. Data on unmodified HGH Fragment 176-191’s IGF-1 effects specifically is more limited.
What receptor do these compounds primarily act on?
Research indicates that both compounds primarily interact with beta-3 adrenergic receptors in adipose tissue. Evidence for this comes from studies in beta-3 receptor knockout mice, where the lipolytic effects of AOD-9604 were substantially reduced compared to wild-type animals.
Are these compounds approved for human use?
Neither compound is approved as a pharmaceutical drug for any indication. AOD-9604 received FDA GRAS status as a food supplement ingredient and progressed through clinical trials, but did not receive drug approval. Both are available for in vitro and preclinical research purposes only.
References
- Heffernan M, Summers RJ, Thorburn A, et al. (2001). The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. PMID: 11713213
- Heffernan MA, Thorburn AW, Fam B, et al. (2001). Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord. PMID: 11673763
- Wilding J. (2004). AOD-9604 Metabolic. Curr Opin Investig Drugs. PMID: 15134286
- Kwon DR, Park GY. (2015). Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model. Ann Clin Lab Sci. PMID: 26275694
Disclaimer: This article is for educational and research purposes only. The information provided does not constitute medical advice, and no claims are made regarding the therapeutic efficacy of any compound discussed. Always consult qualified professionals before beginning any research protocol. CertaPeptides products are sold for laboratory research use only and are not intended for human consumption.